Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
(
1 selected
)
Type
Guidance (402)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Apply filters
Showing 351 to 375 of 402
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Technology appraisal guidance
TBC
Targeted Muscle Reinnervation for refractory pain after limb amputation
Interventional procedures guidance
20 June 2025
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Technology appraisal guidance
11 December 2024
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Technology appraisal guidance
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Technology appraisal guidance
TBC
Technologies for the assessment of attention deficit hyperactivity disorder (ADHD)
Diagnostics guidance
24 October 2024
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]
Technology appraisal guidance
TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition ID6259
Technology appraisal guidance
TBC
Teprotumumab for treating thyroid eye disease ID6432
Technology appraisal guidance
TBC
Third molars (impacted) - prophylactic removal [ID898]
Technology appraisal guidance
TBC
Tirzepatide for managing overweight and obesity [ID6179]
Technology appraisal guidance
30 October 2024
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]
Technology appraisal guidance
TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
Technology appraisal guidance
TBC
Tobacco: preventing uptake, promoting quitting and treating dependence - Cytisine for smoking cessation
NICE guideline
TBC
Topical Antimicrobial dressings for wound care: Late stage assessment
Health technology evaluation
27 March 2025
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Technology appraisal guidance
TBC
Total hip arthroplasty using the superpath approach for osteoarthritis
Interventional procedures guidance
TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Technology appraisal guidance
TBC
Transcatheter aortic valve implantation for native aortic valve regurgitation
Interventional procedures guidance
11 June 2025
Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessment
Health technology evaluation
5 December 2024
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]
Technology appraisal guidance
TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Technology appraisal guidance
10 September 2025
Treatments for non-small-cell lung cancer [ID6234]
Technology appraisal guidance
TBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]
Technology appraisal guidance
25 September 2024
Previous page
1
…
13
14
Current page
15
16
17
Page
15
of
17
Next page
Results per page
10
25
50
All
Back to top